Core Viewpoint - The article highlights significant advancements in the efficacy and safety of the drug Masitide in treating Type 2 Diabetes (T2D), demonstrating its potential for effective blood sugar control and weight loss in patients [4][12]. Group 1: Clinical Research Findings - Two Phase III clinical studies on Masitide were published back-to-back in the journal Nature, marking a first in the field of metabolic and endocrine diseases [6][8]. - The studies, DREAMS-1 and DREAMS-2, focus on Masitide's effectiveness as a monotherapy and in combination with oral hypoglycemic agents, based on clinical data from Chinese patients [8]. Group 2: Drug Mechanism and Benefits - Masitide is the first and only approved GCG/GLP-1 dual-target drug for weight loss and blood sugar reduction, enhancing insulin secretion and promoting satiety [10][12]. - The dual mechanism of action—suppressing appetite and accelerating metabolism—addresses complex metabolic issues such as visceral fat accumulation and insulin resistance in obese patients [10]. Group 3: Clinical Outcomes - The results from the published studies indicate that Masitide outperforms both placebo and Dulaglutide (1.5mg) in blood sugar control and weight loss, while also improving various cardiovascular, liver, and kidney-related indicators [12].

玛仕度肽是信达生物自主开发的全球首个且唯一获批上市的GCG/GLP-1天然双靶减重降糖药物。 据介绍，GLP-1是胰高血糖素样肽-1的英文简称，它在餐后分泌，可促进胰岛素分泌、降低进食后的血 糖，并减缓胃肠道蠕动，造成饱腹感。GLP-1类药物可通过激活GLP-1的受体，增加胰岛素分泌，从而 达到降低血糖和减轻体重的治疗效果。GCG是胰高血糖素的英文缩写，由胰腺中的胰岛α细胞分泌，其 受体主要在肝脏中表达。激活GCG受体可增强脂肪氧化、促进能量消耗、改善肝脏脂肪代谢。 专家介绍，GCG与GLP-1靶点联合，通过"抑制食欲+加速代谢"的双重作用机制，可更好解决肥胖患者 内脏脂肪堆积、胰岛素抵抗等复杂代谢问题。 据介绍，玛仕度肽已在中国获批用于糖尿病和减重两项适应证，并已开展7项Ⅲ期研究，涵盖糖尿病、 肥胖及相关并发症领域。 《自然》发表的两项临床研究结果表明，玛仕度肽在血糖控制和减重方面均优效于安慰剂或度拉糖肽 （1.5mg），同时均显示可改善多项心血管代谢、肝脏和肾脏相关指标，为全球糖尿病合并肥胖等代谢 疾病的治疗提供了新的解决方案。 由我国多家研发单位联合完成的两项关于降糖减重药物的Ⅲ期临床研究成果，北京时间 ...